19-004 - Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001)Status: open
A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)
Patients with Endometrial Carcinoma
|The purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for progression-free survival (PFS) per Response Evaluation Criteria In Solid Tumors version 1.1 (RECIST 1.1) by blinded independent central review (BICR). It is also hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy for overall survival (OS).|
SponsorsThis trial is sponsored by Merck.
Interested in Clinical Trial?
Providers Associated With This Trial
- Rodney P. Rocconi, M.D., F.A.C.O.G.Gynecologic OncologistAssociate Director for Clinical Research; Abraham A. Mitchell Clinical Cancer Research Scholar; Professor of Interdisciplinary Clinical Oncology
- Jennifer M. Scalici, M.D.Gynecologic OncologistChief of Gynecologic Oncology Service; Associate Professor of Interdisciplinary Clinical Oncology
- Jennifer Young Pierce, M.D., M.P.H., F.A.C.O.G.Gynecologic OncologistLeader of Cancer Control and Prevention; Professor of Interdisciplinary Clinical Oncology
- Nathaniel Jones, M.D.Gynecologic OncologistAssistant Professor of Interdisciplinary Clinical Oncology